Copay Accumulators and Maximizers: Policy Shifts and Implications for Patient Access

By Root Woldu

 

For patients on specialty therapies, manufacturer copay assistance can be the difference between staying on treatment and walking away from the pharmacy empty-handed. But a growing share of health plan designs are built to limit how that assistance works — or to drain it entirely before the year is out. Copay accumulators and copay maximizers are two of the most common tools insurers use to do this, and their impact on access programs is significant. Understanding how they work, where policy protections fall short and what can be done about them is increasingly central to how life sciences organizations and patient support teams operate.

Before diving into policy and program implications, it’s beneficial to align terms because although they are often used interchangeably, accumulators and maximizers work differently.

 

Key Definitions

Copay accumulators: A plan rule that says manufacturer copay assistance does not count toward the deductible or out-of-pocket (OOP) maximum. Patients can end up paying more later because those limits still are not met.

Copay maximizers: A benefit design that sets or spreads cost-sharing, so a copay card is used up over time. In many cases, the copay card still does not count toward the deductible or OOP maximum, and costs can jump if the assistance runs out.

Current Policy Landscape

State restrictions cover only a small share of patients

Since 2019, 26 states, Washington, D.C., and Puerto Rico have enacted laws that limit or ban copay accumulators in certain state-regulated health plans. These rules aim to prevent manufacturer assistance from being excluded from a patient’s deductible or OOP maximum, which can raise what the patient owes later in the year.

Even with these laws, only about 17% of commercially insured patients are protected. Most people participate in self-funded employer plans, which generally are not subject to state insurance rules under ERISA, the federal law that governs many employer-sponsored health plans.

Insurers are using maximizer programs instead

As more states moved against accumulators, many insurers shifted to copay maximizer programs. Plans may move high-cost drugs into special benefit categories and set cost-sharing to draw down the full amount of available assistance.

When the assistance runs out, patients can face a sudden jump in what they owe or new barriers at the pharmacy. Because many state laws do not clearly address maximizers, these designs can produce accumulator-like outcomes while sidestepping accumulator-specific limits.

Federal guidance has not materialized

In 2023, a federal court found copay accumulators inconsistent with Affordable Care Act (ACA) cost-sharing requirements, and the government later withdrew its appeal. There still is no clear federal rule on how accumulators or maximizers must be treated nationwide.

For manufacturers and their patient support program partners, that means navigating a patchwork of state rules, plan types and payer practices.

 

How Copay Accumulators and Maximizers Can Impact Patient Affordability Programs (PAPs)

 

Forecasting is less reliable

Accumulators and maximizers can impact PAPs differently depending on state law, plan structure and payer design, which makes forecasting less dependable for starts, persistence and overall impact. Some patients discontinue months later after an unexpected cost increase.

Operational burden continues to increase

Patient support programs carry more day-to-day complexity: tracking state rules, ERISA exemptions, and payer benefit designs, plus verifying coverage and setting patient expectations early so access does not fail later in treatment.

 

How Life Sciences Organizations are Navigating Accumulators and Maximizers

 

Life sciences organizations and patient support programs have adjusted copay assistance strategies to reduce disruption from accumulators and maximizers.

Common approaches include:

• Use alternative payment models, such as a virtual card or debit-style support delivered outside standard secondary copay claims.
• Offer direct reimbursement, where the patient pays first and is reimbursed after the transaction.
• Adopt a payer-of-last-resort structure so assistance applies only after other payment sources are exhausted.
• Adjust program design or limits for patients identified in maximizer programs, balancing support with the risk of midyear cost increases.

 

How AssistRx Helps Mitigate Accumulators and Maximizers

 

When it comes to copay accumulators and maximizers, there is no silver bullet — and no technology-only solution. Addressing these challenges takes the right balance of tech + talent working together.

On the technology side, AssistRx uses Advanced Benefit Verification to identify whether a patient is prescribed a drug likely to be targeted by one of these programs. Those flags are integrated directly into our CRM so that vulnerable patients are surfaced for intervention before a disruption occurs — not after.

On the talent side, our teams bring deep expertise across pharmacy benefit coverage, medical benefit coverage, government and commercial insurance and third-party foundations. When a patient is flagged, our specialists can quickly assess their benefit options, identify alternative coverage solutions and determine the most effective path forward — whether that means routing through a debit card, a reimbursement model, or another compliant payment approach that avoids triggering the adjudicator.

The goal is benefit optimization: making sure each patient gets to — and stays on — their therapy, even when plan designs are working against them.

Our tech + talent:

• Detects and flags potential accumulator or maximizer impact using benefits investigation findings and claim pattern signals.
• Monitors for plan and benefit changes over time so flags and routing stay current.
• Routes patients to compliant support pathways, including alternative payment or reimbursement workflows when appropriate to the manufacturer’s program.
• Provides patient, pharmacy and healthcare provider education on what to expect, including whether assistance is likely to count toward the deductible or OOP maximum.

 

Looking Ahead

 

Copay accumulators and maximizers can create affordability challenges. State action helps some patients, but many people in employer-sponsored coverage, especially self-funded plans, aren’t protected.

Until there is clearer national guidance, it helps to plan for differences across states, plan types and payer policies. The aim is to support continuity of care and avoid unexpected cost spikes — and doing that well requires more than policy tracking. It requires the right technology to identify at-risk patients early, and the right expertise to act on that information before access breaks down.

Connect with AssistRx today to evaluate how accumulators and maximizers may be impacting your access programs — and identify strategies to reduce disruption, improve patient continuity, and optimize program performance.